ELA vs LEGH

Envela Corporation (ELA) presents a stark dichotomy between explosive growth and deteriorating fundamental health. While the company exhibits hyper-growth in revenue (66.6%) and earnings (284.5%), the Piotroski F-Score of 3/9 indicates weak financial health and poor operational efficiency. The stock is currently trading at a premium ($18.50) relative to both its Graham Number ($5.70) and Intrinsic Value ($16.52), with a concerning Forward P/E (52.86) that exceeds its trailing P/E (33.04), suggesting a projected earnings slowdown.

LEGH presents a classic 'value trap' scenario, characterized by a weak Piotroski F-Score of 3/9 and severe fundamental deterioration. While the company maintains an exceptionally clean balance sheet with zero debt and high profit margins, these are overshadowed by a collapse in growth, with revenue and earnings plummeting by approximately 30% and 42% respectively. The stock trades below its Graham Number ($29.48) but significantly above its growth-based intrinsic value ($12.18), suggesting that current valuation metrics are lagging behind the rapid decline in operational performance.